Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Inclusion criteria : * Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) ≥7%. * Estimated glomerular filtration rate (eGFR) ≥25 and ≤60 milliliter/minute (mL/min)/1.73 square meter (m\^2). * Age 18 years or older with at least one major cardiovascular risk factor or age 55 years or older with at least two minor cardiovascular risk factors. * Signed written informed consent. Exclusion criteria: * Antihyperglycemic treatment has not been stable within 12 weeks prior to screening. * Planned coronary procedure or surgery after randomization. * Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization. * Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the study. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.